Effects of Prazosin on Provoked Alcohol Craving and Autonomic and Neuroendocrine Response to Stress in Alcohol Use Disorder.
Adrenergic alpha-1 Receptor Antagonists
/ therapeutic use
Adrenocorticotropic Hormone
/ metabolism
Adult
Alcoholism
/ metabolism
Anxiety
/ psychology
Anxiety Disorders
/ psychology
Craving
Cues
Double-Blind Method
Female
Heart Rate
/ physiology
Humans
Hydrocortisone
/ metabolism
Imagery, Psychotherapy
Male
Middle Aged
Prazosin
/ therapeutic use
Stress, Psychological
Alcohol Use Disorders
Anxiety
Craving
Heart rate
Prazosin
Stress
Journal
Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
12
03
2020
accepted:
13
05
2020
pubmed:
26
5
2020
medline:
8
9
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Chronic alcohol use results in changes to stress biology and autonomic arousal contributing to acute alcohol withdrawal symptoms, neuroendocrine tolerance of the hypothalamic-pituitary-adrenal axis responses, high stress-induced craving, and risk of alcohol relapse. Thus, stress coping and recovery from alcohol during early abstinence may be jeopardized by such stress system dysfunction. Significant preclinical evidence suggests that noradrenergic disruption may contribute to these alcohol-related stress arousal changes and that alpha-1 adrenergic antagonists, such as prazosin, may normalize these stress system adaptations and reduce alcohol intake. Thus, we hypothesized that prazosin would reduce stress-induced craving and improve neuroendocrine and autonomic response to stress and alcohol cue exposure during early abstinence. We secondarily also assessed the role of lifetime anxiety disorders on these prazosin effects. Forty inpatient treatment-seeking alcohol-dependent individuals were randomly assigned to receive placebo (n = 18) or 16 mg/d, T.I.D., prazosin (n = 22) in a double-blind manner, titrated over 2 weeks. In weeks 3 to 4 after achieving full dose, patients were exposed to 3 5-minute personalized guided imagery conditions (stress cue, alcohol cue, neutral/relaxing cue), on 3 consecutive days in a random, counterbalanced order. Alcohol craving, anxiety, heart rate, cortisol, and adrenocorticotropic hormone (ACTH) levels were assessed at baseline, following imagery and at repeated recovery timepoints. Prazosin reduced stress cue-induced alcohol craving (p < 0.05) and stress- and alcohol cue-induced anxiety (p < 0.05) and increased heart rate responses in all imagery conditions (p < 0.05). Prazosin lowered basal cortisol and ACTH (p's < 0.05) and attenuated stress cue-induced rises in cortisol (p < 0.05) versus placebo. Finally, in those without lifetime anxiety disorder, the placebo group showed stress- and alcohol cue-induced increases in cortisol (p's < 0.05), while the prazosin group did not. Prazosin may attenuate stress cue-induced alcohol craving and anxiety during early abstinence while improving adrenergic and stress system function, effects which are independent of a history of lifetime anxiety disorders.
Sections du résumé
BACKGROUND
Chronic alcohol use results in changes to stress biology and autonomic arousal contributing to acute alcohol withdrawal symptoms, neuroendocrine tolerance of the hypothalamic-pituitary-adrenal axis responses, high stress-induced craving, and risk of alcohol relapse. Thus, stress coping and recovery from alcohol during early abstinence may be jeopardized by such stress system dysfunction. Significant preclinical evidence suggests that noradrenergic disruption may contribute to these alcohol-related stress arousal changes and that alpha-1 adrenergic antagonists, such as prazosin, may normalize these stress system adaptations and reduce alcohol intake. Thus, we hypothesized that prazosin would reduce stress-induced craving and improve neuroendocrine and autonomic response to stress and alcohol cue exposure during early abstinence. We secondarily also assessed the role of lifetime anxiety disorders on these prazosin effects.
METHODS
Forty inpatient treatment-seeking alcohol-dependent individuals were randomly assigned to receive placebo (n = 18) or 16 mg/d, T.I.D., prazosin (n = 22) in a double-blind manner, titrated over 2 weeks. In weeks 3 to 4 after achieving full dose, patients were exposed to 3 5-minute personalized guided imagery conditions (stress cue, alcohol cue, neutral/relaxing cue), on 3 consecutive days in a random, counterbalanced order. Alcohol craving, anxiety, heart rate, cortisol, and adrenocorticotropic hormone (ACTH) levels were assessed at baseline, following imagery and at repeated recovery timepoints.
RESULTS
Prazosin reduced stress cue-induced alcohol craving (p < 0.05) and stress- and alcohol cue-induced anxiety (p < 0.05) and increased heart rate responses in all imagery conditions (p < 0.05). Prazosin lowered basal cortisol and ACTH (p's < 0.05) and attenuated stress cue-induced rises in cortisol (p < 0.05) versus placebo. Finally, in those without lifetime anxiety disorder, the placebo group showed stress- and alcohol cue-induced increases in cortisol (p's < 0.05), while the prazosin group did not.
CONCLUSIONS
Prazosin may attenuate stress cue-induced alcohol craving and anxiety during early abstinence while improving adrenergic and stress system function, effects which are independent of a history of lifetime anxiety disorders.
Identifiants
pubmed: 32449942
doi: 10.1111/acer.14378
pmc: PMC7572699
mid: NIHMS1606265
doi:
Substances chimiques
Adrenergic alpha-1 Receptor Antagonists
0
Adrenocorticotropic Hormone
9002-60-2
Hydrocortisone
WI4X0X7BPJ
Prazosin
XM03YJ541D
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1488-1496Subventions
Organisme : NIDA NIH HHS
ID : K01 DA046561
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024139
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIAAA NIH HHS
ID : K02 AA023566
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA026514
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA020504
Pays : United States
Informations de copyright
© 2020 by the Research Society on Alcoholism.
Références
Alcohol. 2008 Mar;42(2):91-7
pubmed: 18358987
Arch Gen Psychiatry. 2011 Sep;68(9):942-52
pubmed: 21536969
Neuropsychopharmacology. 2009 Apr;34(5):1198-208
pubmed: 18563062
Neuron. 2008 Jul 10;59(1):11-34
pubmed: 18614026
Am J Psychiatry. 2018 Dec 1;175(12):1216-1224
pubmed: 30153753
Alcohol. 2006 Apr;38(3):173-7
pubmed: 16905443
Psychopharmacology (Berl). 2011 Nov;218(1):89-99
pubmed: 21318567
Addict Biol. 2016 Jul;21(4):904-14
pubmed: 26037245
Alcohol Clin Exp Res. 2007 Mar;31(3):395-403
pubmed: 17295723
Alcohol Clin Exp Res. 2015 May;39(5):808-17
pubmed: 25827659
Alcohol Clin Exp Res. 2012 May;36(5):881-6
pubmed: 21981346
Ann N Y Acad Sci. 2008 Oct;1141:105-30
pubmed: 18991954
Neuropharmacology. 2017 Aug 1;122:136-147
pubmed: 28159647
Psychoneuroendocrinology. 2019 Feb;100:180-189
pubmed: 30347319
J Abnorm Psychol. 1983 Aug;92(3):276-306
pubmed: 6619405
Alcohol Clin Exp Res. 2000 Dec;24(12):1836-49
pubmed: 11141043
Alcohol Alcohol. 2003 Mar-Apr;38(2):189-93
pubmed: 12634269
Am J Health Syst Pharm. 2008 Apr 15;65(8):716-22
pubmed: 18387899
Alcohol Clin Exp Res. 2013 Feb;37(2):202-12
pubmed: 22758213
Neuropsychopharmacology. 2008 Mar;33(4):796-805
pubmed: 17568398
Trends Mol Med. 2018 Feb;24(2):173-186
pubmed: 29396148
Drug Alcohol Depend. 2017 Aug 1;177:23-28
pubmed: 28551590
J Addict Med. 2018 Sep/Oct;12(5):339-345
pubmed: 29664896
Psychophysiology. 1980 Mar;17(2):179-92
pubmed: 7375619
Clin Psychol Rev. 2012 Jun;32(4):301-15
pubmed: 22459791
Alcohol Clin Exp Res. 2016 Jan;40(1):178-86
pubmed: 26683790
Alcohol Clin Exp Res. 2009 Feb;33(2):255-63
pubmed: 18945226
Alcohol Clin Exp Res. 2009 Feb;33(2):264-72
pubmed: 19032582
Psychopharmacology (Berl). 2000 Oct;152(2):140-8
pubmed: 11057517
Psychoneuroendocrinology. 2005 Oct;30(9):880-91
pubmed: 15975729
Alcohol Clin Exp Res. 2005 Jul;29(7):1351-5
pubmed: 16088999
Alcohol Clin Exp Res. 2018 Mar;42(3):634-645
pubmed: 29286542
Am J Psychiatry. 1996 Jan;153(1):83-92
pubmed: 8540598
J Stud Alcohol. 2006 Sep;67(5):700-6
pubmed: 16847538
Psychopharmacology (Berl). 2003 Oct;170(1):62-72
pubmed: 12845411
Alcohol Clin Exp Res. 2012 Feb;36(2):351-60
pubmed: 21919922
Biol Psychiatry. 2007 Apr 15;61(8):928-34
pubmed: 17069768
J Psychopharmacol. 2017 Jul;31(7):830-840
pubmed: 28440105
J Stud Alcohol Suppl. 1994 Dec;12:70-5
pubmed: 7723001
Psychosom Med. 1992 Jul-Aug;54(4):422-35
pubmed: 1502284
Alcohol Clin Exp Res. 2013 Jan;37(1):8-15
pubmed: 22671690
Neuropharmacology. 2014 Jan;76 Pt B:370-82
pubmed: 23747571
Drug Alcohol Depend. 2019 Nov 1;204:107569
pubmed: 31574406